AbCellera Biologics Inc.
ABCL$789M
Small CapNASDAQPharmaceutical PreparationsBiotechnology🇺🇸North AmericaVANCOUVER596 employees
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
ABCL News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ABCL635 | Phase 2 | Vasomotor Symptoms Associated With Menopause | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply